Company Filing History:
Years Active: 2003
Title: Albert B DeLeo: Innovator in Tumor Immunology
Introduction
Albert B DeLeo is a prominent inventor based in Pittsburgh, PA (US). He is known for his significant contributions to the field of tumor immunology. His work focuses on developing therapeutic methods for treating tumor-bearing patients, which has the potential to impact cancer treatment significantly.
Latest Patents
Albert B DeLeo holds a patent for a cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine. This patent describes an isolated cDNA molecule that comprises an amino acid sequence encoding an amino-terminal protein fragment of murine glycoprotein 110. The patent also discloses therapeutic methods for treating tumor-bearing patients and prophylactic methods for vaccinating patients. Additionally, an animal model for studying tumors is included in the patent.
Career Highlights
Albert B DeLeo is affiliated with the University of Pittsburgh, where he continues to advance research in tumor immunology. His work has garnered attention for its innovative approach to cancer treatment and prevention.
Collaborations
He has collaborated with notable colleagues, including Douglas Loftus and Ettore Appella, to further enhance the research and development of cancer therapies.
Conclusion
Albert B DeLeo's contributions to tumor immunology through his patent and research at the University of Pittsburgh highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in cancer treatment.